Renaissance Technologies LLC Boosts Holdings in Ralliant Corporation $RAL

Renaissance Technologies LLC lifted its stake in shares of Ralliant Corporation (NYSE:RAL) by 28.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 371,082 shares of the company’s stock after purchasing an additional 82,580 shares during the period. Renaissance Technologies LLC’s holdings in Ralliant were worth $15,433,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Gabelli Funds LLC raised its position in shares of Ralliant by 28.2% during the 1st quarter. Gabelli Funds LLC now owns 38,257 shares of the company’s stock worth $1,591,000 after purchasing an additional 8,421 shares during the last quarter. Gamco Investors INC. ET AL boosted its holdings in Ralliant by 7.9% in the 1st quarter. Gamco Investors INC. ET AL now owns 52,261 shares of the company’s stock worth $2,174,000 after buying an additional 3,833 shares during the last quarter. Bank of Nova Scotia boosted its holdings in Ralliant by 571.1% in the 1st quarter. Bank of Nova Scotia now owns 162,400 shares of the company’s stock worth $6,754,000 after buying an additional 138,200 shares during the last quarter. Sei Investments Co. increased its stake in Ralliant by 193.7% during the 1st quarter. Sei Investments Co. now owns 182,342 shares of the company’s stock worth $7,583,000 after buying an additional 120,248 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Ralliant during the 1st quarter worth approximately $4,525,000.

Ralliant Stock Down 1.8%

RAL stock opened at $65.78 on Friday. The company has a market cap of $7.36 billion and a price-to-earnings ratio of -6.06. The company has a current ratio of 1.52, a quick ratio of 1.05 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $75.41. The firm has a 50-day moving average of $67.20 and a two-hundred day moving average of $54.34.

Ralliant (NYSE:RAL) last issued its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, analysts forecast that Ralliant Corporation will post 2.83 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

More Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Analysts Set New Price Targets

A number of equities analysts have commented on RAL shares. Citigroup increased their target price on Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a report on Friday. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Truist Financial reiterated a “buy” rating and set a $82.00 price target (up from $68.00) on shares of Ralliant in a research report on Friday. Wall Street Zen downgraded Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, July 26th. Finally, Royal Bank Of Canada raised their price objective on Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.